diabetestalk.net

Humalog Junior Kwikpen Ndc

Humalog® Junior Kwikpen® Now Available In The U.s. For People With Diabetes

Humalog® Junior Kwikpen® Now Available In The U.s. For People With Diabetes

INDIANAPOLIS, Oct. 4, 2017 /PRNewswire/ -- Humalog® Junior KwikPen® [insulin lispro injection 100 units/mL] is now available by prescription for the treatment of diabetes in the U.S. This innovation is the latest in the treatment and delivery options Eli Lilly and Company (NYSE: LLY) offers for people with type 1 or type 2 diabetes. Humalog Junior KwikPen is the only prefilled, disposable half-unit insulin pen. In June 2017, the U.S. Food and Drug Administration (FDA) approved Humalog Junior KwikPen for the treatment of diabetes. In September 2017, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for Humalog Junior KwikPen in the European Union and is pending final approval, expected later this year. "Learning how to inject insulin can be overwhelming, especially for newly diagnosed children and their caregivers. People often feel shock and anxiety, and may struggle with the reality of fitting diabetes into daily life," said Sherry Martin, M.D., vice president, Global Medical Affairs, Lilly Diabetes. "We hope to help take away some of the worries about the injection process with Humalog Junior KwikPen. Because it is prefilled, there are fewer steps for people to learn, and the half-unit increments make dosing more precise." Humalog Junior KwikPen, which is lighter and shorter than other half-unit insulin pens, provides an option for people who prefer a prefilled pen and need the precision of half-unit dosing, such as those with insulin sensitivity and some older adults for whom rounding to the nearest whole-unit dose is not adequate. Until now, the only way to deliver half units of insulin with a pen was through a reusable pen, which requires users to remove and load cartridges. Humalog Junior K Continue reading >>

Indications And Usage For Humalog

Indications And Usage For Humalog

Generic Name: insulin lispro Dosage Form: injection, solution Humalog is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. Humalog Dosage and Administration Important Administration Instructions Always check insulin labels before administration [see Warnings and Precautions (5.4)]. Inspect Humalog visually before use. It should appear clear and colorless. Do not use Humalog if particulate matter or coloration is seen. Do NOT mix Humalog U-100 with other insulins when administering using a continuous subcutaneous infusion pump. Do NOT transfer Humalog U-200 from the KwikPen to a syringe for administration [see Warnings and Precautions (5.4)]. Do NOT perform dose conversion when using any Humalog U-100 or U-200 KwikPens. The dose window shows the number of insulin units to be delivered and no conversion is needed. Humalog U-100 and U-200 KwikPens are designed to dial doses in increments of 1 unit. Humalog Junior KwikPen is designed to dial doses in 0.5 (1/2) unit increments. Do NOT mix Humalog U-200 with any other insulins. Do NOT administer Humalog U-200 using a continuous subcutaneous infusion pump (i.e., insulin pump). Do NOT administer Humalog U-200 intravenously. Route of Administration Subcutaneous Injection: Humalog U-100 or U-200 Administer the dose of Humalog U-100 or Humalog U-200 within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see Adverse Reactions (6)]. Humalog administered by subcutaneous injection should generally be used in regimens with an intermediate- or lon Continue reading >>

Why Humalog U-100 Kwikpen Might Be Right For Your Patients

Why Humalog U-100 Kwikpen Might Be Right For Your Patients

Humalog KwikPen is a small, lightweight, prefilled insulin pen for patients with type 2 or type 1 diabetes who want a portable device. Humalog KwikPen should not be refrigerated after first use and can be taken just about anywhere. Patients can carry it in their purse, backpack, or pocket because it’s the size of a marker. Remind your patients to always carry an extra pen. In-use Humalog KwikPen should be stored at room temperature, below 86°F (30°C). Humalog KwikPen must be used within 28 days or be discarded, even if it still contains Humalog. Humalog U-100 KwikPen can be an easy-to-use, easy-to-inject prefilled pen option*14 Easy to set the dose*14 Easy to see the numbers*14 Easy to dial up and back down for dose selection*14 Easy to dispense maximum dose of 60 units*14 Allows patients or caregivers to discreetly deliver insulin To help patients and their caregivers learn how to inject using Humalog KwikPen, please click to access the Humalog U-100 KwikPen Instructions for Use. *Humalog KwikPen Design Validation User Study included adult male and female participants with type 1 and type 2 diabetes. Of the total 150 study participants, 56 were insulin-naïve, 42 were currently administering insulin with a vial and syringe, and 52 were experienced insulin pen users. Pen needles for use with Humalog KwikPen Humalog KwikPen is suitable for use with Becton Dickinson (BD) needles (sold separately and may require a separate prescription). BD offers a comprehensive line of advanced protection products. For more information about BD pen needles, visit the BD Diabetes website for healthcare professionals. Pens and needles are for single-patient use only and should not be shared, even in healthcare facilities, as infection or disease can be spread from one person to another Continue reading >>

Humalog Junior Kwikpen Ndc

Humalog Junior Kwikpen Ndc

You were looking forHumalog Junior Kwikpen Ndc? You most likely will find some useful information in this article, come have a quick look! Taking insulin or other diabetes medicines is typically part of treating diabetes Together with healthy food options and physical activity, medicine can help you manage the disease. Some other treatment options are likewise readily available. What medications might I take for diabetes? The medication you take will differ by your type of diabetes and how well the medication controls your blood glucose levels, likewise called blood sugar. Other factors, such as your other health conditions, medication expenses, and your daily schedule may contribute in exactly what diabetes medication you take. Some people with type 2 diabetes can handle their disease by making healthy food choices and being more physically active. Many people with type 2 diabetes requirement diabetes medications as well. These medicines might include diabetes pills or medicines you inject under your skin, such as insulin. In time, you may need more than one diabetes medicine to control your blood sugar. Even if you do not take insulin, you may require it at unique times, such as throughout pregnancy or if you are in the medical facility. If you have gestational diabetes, you must initially try to manage your blood sugar level by making healthy food choices and getting regular physical activity. If you cannot reach your blood glucose target, your healthcare team will talk with you about diabetes medicines, such as insulin or the diabetes pill metformin, that might be safe for you to take throughout pregnancy. Your healthcare team may begin you on diabetes medications right now if your blood glucose is very high. No matter what kind of diabetes you have, taking diabete Continue reading >>

Novolog® (insulin Aspart Injection) 100 U/ml Indications And Usage

Novolog® (insulin Aspart Injection) 100 U/ml Indications And Usage

NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. NovoLog® (insulin aspart injection) 100 U/mL is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Patients using NovoLog® vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously under close medical supervision and the frequency of blood glucose monitoring should be increased. Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is re Continue reading >>

Dailymed - Search Results For Insulin

Dailymed - Search Results For Insulin

SEARCH RESULTS for: Insulin [Drug Class] (57 results) NDC Code(s): 0024-5924-10, 0024-5925-00, 0024-5925-01, 0024-5925-05 NDC Code(s): 47918-874-90, 47918-878-90, 47918-880-18, 47918-882-36, view more 47918-884-63, 47918-891-90, 47918-894-63, 47918-902-18 NDC Code(s): 0002-7715-01, 0002-7715-59, 0002-7715-63 NDC Code(s): 0069-0050-19, 0069-0050-53, 0069-0050-85, 0069-0707-37, view more NDC Code(s): 0169-3201-11, 0169-3201-90, 0169-3204-15, 0169-3204-97 NDC Code(s): 0002-7510-01, 0002-7510-17, 0002-7510-99, 0002-7516-01, view more 0002-7516-59, 0002-7516-99, 0002-7712-01, 0002-7712-27, 0002-7712-61, 0002-7712-99, 0002-7714-01, 0002-7714-59, 0002-7714-61, 0002-8799-01, 0002-8799-59, 0002-8799-61, 0002-8799-99 NDC Code(s): 54868-5108-0, 54868-5836-0, 54868-5899-0 NDC Code(s): 0002-7512-01, 0002-7512-99, 0002-8798-01, 0002-8798-59, view more NDC Code(s): 0002-7511-01, 0002-7511-99, 0002-8797-01, 0002-8797-59, view more NDC Code(s): 0002-8715-01, 0002-8715-17, 0002-8715-99, 0002-8803-01, view more 0002-8803-59, 0002-8803-61 NDC Code(s): 0002-8315-01, 0002-8315-17, 0002-8315-99, 0002-8805-01, view more Why is DailyMed no longer displaying pill images on the Search Results and Drug Info pages? Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage , we no longer display the RxImage pill images associated with drug labels. We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels. Continue reading >>

July 2018 Ndc - Hcpcs Crosswalk

July 2018 Ndc - Hcpcs Crosswalk

Effective July 1, 2018 through September 30, 2018 Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) Coagulation Factor IX, Recombinant (Ixinity) METRONIDAZOLE 500 MG INJ USP LIFECARE 100ML FILL Olanzapine short acting intramuscular injection Olanzapine short acting intramuscular injection Olanzapine short acting intramuscular injection Sodium Chloride, Hypertonic (3% - 5% infusion) Sodium Chloride, Hypertonic (3% - 5% infusion) Sodium Chloride, Hypertonic (3% - 5% infusion) Sodium Chloride, Hypertonic (3% - 5% infusion) HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS , America's Health Insurance Plans , and Blue Cross and Blue Shield Association ). CPT is a registered trademark of the American Medical Association (AMA). All rights reserved. Continue reading >>

April 2018 Formulary Changes: 2018 Medicare Part D Drug Lists Now Updated With 486 New Prescription Drugs - Part 2 Of 5 - Drugs Starting With The Letters D-h.

April 2018 Formulary Changes: 2018 Medicare Part D Drug Lists Now Updated With 486 New Prescription Drugs - Part 2 Of 5 - Drugs Starting With The Letters D-h.

April 2018 formulary changes: 2018 Medicare Part D drug lists now updated with 486 new prescription drugs - Part 2 of 5 - Drugs starting with the letters D-H. April 2018 formulary changes: 2018 Medicare Part D drug lists now updated with 486 new prescription drugs - Part 2 of 5 - Drugs starting with the letters D-H. The April, 2018 Medicare Part D plan formulary data (or drug list updates) includes the addition of 737 new National Drug Codes (NDCs) to the Medicare Part D program. These NDCs represent 486 different drugs, many with multiple strengths. There are so many new NDCs, that we have to split the list into 5 parts. This article will cover drugs starting with the letters D through H. Here are links to A-C , I-M , N-P , and Q-Z . Fifty-seven new NDC generic equivalents were added, including including DACTINOMYCIN [Cosmegen], DAPTOMYCIN [Cubicin], EFAVIRENZ [Sustiva], ELETRIPTAN HBR [Relpax], ESCITALOPRAM OXALATE [Lexapro],ESOMEPRAZOLE MAG [Nexium], ETHYNODIOL-ETH ESTRA [ZOVIA], ETODOLAC [LODINE], FENOFIBRATE [LIPOFEN], FENOFIBRIC ACID [TRILIPIX], FOSAMPRENAVIR [Lexiva], GLATIRAMER [Copaxone], Hepatitis B Surface Antigen Vaccine [Recombivax], Human-Bovine Reassortant Rotavirus Oral Vaccine [RotaTeq], HYDROXYPROGESTERONE [MAKENA], amongst others. See details in the chart below. As a reminder, the NDC uniquely identifies a particular manufacturer, drug-strength,and packaging combination. The NDC for your medication is often shownon your prescription bottle as an 11-digit code (see the charts below)or could be formatted as 00000-0000-00 where the first set of numbersidentifies the manufacturer, the second set of number identifies thedrug and strength, and the third set of numbers identifies thepackaging. New NDCs can be added to the Medicare Part D program for a numbe Continue reading >>

Dailymed - Humalog- Insulin Lispro Injection, Solution Humalog Kwikpen - Insulin Lispro Injection, Solution

Dailymed - Humalog- Insulin Lispro Injection, Solution Humalog Kwikpen - Insulin Lispro Injection, Solution

5.1 Never Share a HUMALOG KwikPen, Cartridge, Reusable Pen Compatible with Lilly 3 mL Cartridges1, or Syringe Between Patients HUMALOG KwikPens, cartridges, and reusable pens compatible with Lilly 3 mL cartridges must never be shared between patients, even if the needle is changed. Patients using HUMALOG vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens. 5.2 Hyper- or Hypoglycemia with Changes in Insulin Regimen Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia [see Warnings and Precautions ( 5.3 )] or hyperglycemia. These changes should be made cautiously and under close medical supervision and the frequency of blood glucose monitoring should be increased. Hypoglycemia is the most common adverse reaction associated with insulins, including HUMALOG. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions ( 7 )], or in patients who experience recurrent hypoglycemia. The risk of hypoglycemia after an injection is related to the duration of action of the insulin and, in general, is highest when the glucose low Continue reading >>

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

Name of Company corresponding to the labeler code segment of the ProductNDC. Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the Document Type of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Sometimes called the generic name, this is usually the active ingredient(s) of the product. Also known as the trade name. It is the name of the product chosen by the labeler. A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (XR) or sleep aid (PM). Although many companies follow certain naming conventions for suffices, there is no recognized standard. The following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved. This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV. The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC. 5 SYRINGE IN 1 CARTON (0002-7714-59) > 3 ML IN 1 SYRINGE (0002-7714-01) A description of the size and type of packaging in sentence form. Multilevel packages will hav Continue reading >>

Drug Information On Humalog - Eli Lilly And Company | Pharmaguru.com

Drug Information On Humalog - Eli Lilly And Company | Pharmaguru.com

Sections or subsections omitted from the full prescribing information are not listed. HUMALOG is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. 2.1 Important Administration Instructions Always check insulin labels before administration [see Warnings and Precautions ( 5.4 )]. Inspect HUMALOG visually before use. It should appear clear and colorless. Do not use HUMALOG if particulate matter or coloration is seen. Do NOT mix HUMALOG U-100 with other insulins when administering using a continuous subcutaneous infusion pump. Do NOT transfer HUMALOG U-200 from the KwikPen to a syringe for administration [see Warnings and Precautions ( 5.4 )]. Do NOT perform dose conversion when using any HUMALOG U-100 or U-200 KwikPens. The dose window shows the number of insulin units to be delivered and no conversion is needed. HUMALOG U-100 and U-200 KwikPens are designed to dial doses in increments of 1 unit. HUMALOG Junior KwikPen is designed to dial doses in 0.5 (1/2) unit increments. Do NOT mix HUMALOG U-200 with any other insulins. Do NOT administer HUMALOG U-200 using a continuous subcutaneous infusion pump (i.e., insulin pump). Do NOT administer HUMALOG U-200 intravenously. Subcutaneous Injection: HUMALOG U-100 or U-200 Administer the dose of HUMALOG U-100 or HUMALOG U-200 within fifteen minutes before a meal or immediately after a meal by injection into the subcutaneous tissue of the abdominal wall, thigh, upper arm, or buttocks. To reduce the risk of lipodystrophy, rotate the injection site within the same region from one injection to the next [see Adverse Reactions ( 6 )]. HUMALOG administered by subcutaneous injection should generally be used in regimens with an intermediate- or long-acting insulin. Conti Continue reading >>

0002-7714 : Humalog 100 [iu]/ml Subcutaneous Injection, Solution

0002-7714 : Humalog 100 [iu]/ml Subcutaneous Injection, Solution

0002-7714 : Humalog 100 [Iu]/Ml Subcutaneous Injection, Solution 0002-7714-59: 5 SYRINGE IN 1 CARTON (0002771459) > 3 ML IN 1 SYRINGE (0002771401) 0002-7714-61: 1 SYRINGE IN 1 CARTON (0002771461) > 3 ML IN 1 SYRINGE Byetta give leg pain. Do Novolog have muscle and pain sideaffects. I want to try Novolog pen. ## Byetta should not cause... 1reply Notice: The MedsChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us . Join over 75,000 subscribers and we'll send you a Drugs Top Prescription Drugs Drug Categories National Drug Code Database Half Life Calculator Recent FDA Approvals Current Health News What are people searching? Generic Me Alprazolam Pain White Pill Blue Specks No Imprint Antibiotics Pills Difference Between Dytor Plus Search Support Vitamin B C And E Can Be Take Together G037 Citalopram Hydrobromide 20 Mg Anneal 3 More Recent Topics ... This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer . Site content is Copyright 2005-2018 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 11 May 2018. Copyright 2005-2018 All Rights Reserved. MedsChat and The People's Medicine Community are registe Continue reading >>

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

0002-7714-59 Ndc Code | Humalog | Human Prescription Drug

Name of Company corresponding to the labeler code segment of the ProductNDC. Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the Document Type of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Sometimes called the generic name, this is usually the active ingredient(s) of the product. Also known as the trade name. It is the name of the product chosen by the labeler. A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (XR) or sleep aid (PM). Although many companies follow certain naming conventions for suffices, there is no recognized standard. The following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved. This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV. The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC. 5 SYRINGE IN 1 CARTON (0002-7714-59) > 3 ML IN 1 SYRINGE (0002-7714-01) A description of the size and type of packaging in sentence form. Multilevel packages will hav Continue reading >>

What Are The Possible Side Effects Of Insulin Lispro (humalog, Humalog Cartridge, Humalog Kwikpen, Humalog Pen)?

What Are The Possible Side Effects Of Insulin Lispro (humalog, Humalog Cartridge, Humalog Kwikpen, Humalog Pen)?

HUMALOG (insulin lispro) Injection DESCRIPTION HUMALOG® (insulin lispro injection) is a rapid-acting human insulin analog used to lower blood glucose. Insulin lispro is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. Insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. Chemically, it is Lys(B28), Pro(B29) human insulin analog and has the empirical formula C257H383N65O77S6 and a molecular weight of 5808, both identical to that of human insulin. HUMALOG has the following primary structure: HUMALOG is a sterile, aqueous, clear, and colorless solution. Each milliliter of HUMALOG U-100 contains insulin lispro 100 units, 16 mg glycerin, 1.88 mg dibasic sodium phosphate, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.0197 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. Each milliliter of HUMALOG U-200 contains insulin lispro 200 units, 16 mg glycerin, 5 mg tromethamine, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.046 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%. font size A A A 1 2 3 4 5 Next What is Type 2 Diabetes? The most common form of diabetes is type 2 diabetes, formerly called non-insulin dependent diabetes mellitus or "adult onset" diabetes, so-called because it typically develops in adults over age 35, though it can develop at any age. Type 2 diabetes i Continue reading >>

0002-7714 Ndc - Humalog (insulin Lispro)

0002-7714 Ndc - Humalog (insulin Lispro)

0002-7714 NDC - HUMALOG (INSULIN LISPRO) 5 SYRINGE in 1 CARTON (0002-7714-59) > 3 mL in 1 SYRINGE (0002-7714-01) 1 SYRINGE in 1 CARTON (0002-7714-61) > 3 mL in 1 SYRINGE The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the Document Type field of the Structured Product Listing. The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes. A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (XR) or sleep aid (PM). Although many companies follow certain naming conventions for suffices, there is no recognized standard. The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product. The translation of the route code submitted by the firm, indicating route of administration. This is the date that the labeler indicates was the start of its marketing of the drug product. Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls u Continue reading >>

More in diabetes